Literature DB >> 25626936

Outcomes from mesenteric-portal axis resection during pancreatectomy.

Enio Campos Amico1, José Roberto Alves1, Samir Assi João1, Ricardo Wagner da Costa Moreira1, José Linhares da Silva Neto2, Joafran Alexandre Costa de Medeiros1.   

Abstract

BACKGROUND: Due to their complexity and risks, mesenteric-portal axis resection and reconstruction during the pancreatectomy procedure were not recommended back in the early nineties. However, as per technical improvements and the reduction in morbidity and mortality rates, they have been routinely indicated in large medical centers. AIM: To show results from cases of patients subjected to mesenteric-portal axis resection during pancreatectomy.
METHOD: Patients subjected to mesenteric-portal axis resection during pancreatectomy were prospectively and consecutively assessed. The procedure was indicated according to anatomical criteria defined by imaging exams or intraoperative assessment.
RESULTS: Ten patients, half of them were male, with mean age of 55.7 years (40-76) were included. The most frequent underlying diseases were pancreatic adenocarcinoma and Frantz tumor. The circumferential resection of the portal vein associated with the superior mesenteric vein with splenic vein ligature (4 cases=40%) and the primary anastomosis of the vascular stumps (5 cases=50%) were, respectively, the most performed types of vascular resection and reconstruction. Surgery time ranged from 480 to 600 minutes (average=556 minutes) and postoperative hospitalization time ranged from 9 to 114 days (average=34.8 days). Morbidity rate was 60%, and clinical pancreatic fistula (grade B and C) was the most common complication (3 cases=30%). Mortality rate was 10% (1 case).
CONCLUSION: Mesenteric-portal axis resection is a valid technical procedure. It should be taken into account after a clinical assessment that included not only the patients' clinical condition but also the technical and anatomical conditions of the mesenteric-portal axis tumor infiltration as well as life expectancy based on the patient's cancer prognosis.

Entities:  

Mesh:

Year:  2014        PMID: 25626936      PMCID: PMC4743219          DOI: 10.1590/S0102-67202014000400009

Source DB:  PubMed          Journal:  Arq Bras Cir Dig        ISSN: 0102-6720


INTRODUCTION

The first resection and reconstruction of part of the mesenteric-portal axis (MPA) during pancreaticoduodenectomy was reported by Moore et al.[8], in 1951. However, due to its complexity and risks, such procedure was considered as contraindicated[6] until the early 1990s. Since then, it started being routinely performed, due to the reduction in morbidity and mortality rates achieved by the technical improvement in medical centers where pancreatic resections are performed. In our country, the outcomes from MPA resection are little disclosed. The current study aims to demonstrate outcomes from patients subjected to MPA resection during pancreatectomy.

METHOD

This study was approved by the Ethics Committees of Onofre Lopes University Hospital, Federal University of Rio Grande do Norte and Liga Norte-Riograndense Against Cancer, Natal, RN, Brazil. Patients who underwent MPA resection during pancreatectomies performed from April 2007 to July 2014 in order to treat pancreatic or peripancreatic diseases were prospectively and consecutively assessed. MPA resection was indicated to patients with pancreatic tumors according to essentially anatomical criteria defined during preoperative imaging examinations or intraoperative evaluation. Thus, the procedure was indicated in cases in which, in order to completely remove the pancreatic lesion, it was also necessary to resect part of the portal vein, superior mesenteric vein or the splenic vein at the MPA confluence and, in addition, a vascular reconstruction procedure was feasible. Some technical principles were used: 1) the end of the surgical specimen dissection was the appropriate moment for MPA resection and reconstruction, when it was totally free from other anatomical structures; 2) whenever possible, a choice was made for the primary anastomosis with vascular stumps from the MPA itself; 3) 2500 - 5000 UI sodium heparin was intravenously administered before clamping; 4) anastomosis was performed by using continuous polypropylene suture 6-0 (growth factor from 1 to 1.5 cm was used for anastomosis expansion after unclamping); 5) a vascular graft was used in the longest resections or in those in which the vascular stumps approximation generated stress. Vascular surgeon assistance was requested in order to perform vascular reconstruction in the graft cases. The remaining technical steps related to pancreatic resection, transit reconstruction, cavity drainage and postoperative care were described in a previous study[1]. As for the pancreatic fistula diagnosis, it was used the criteria from the International Study Group on Pancreatic Fistula Definition[2]. The diagnosis of bleeding and delayed postoperative gastric emptying was based on definitions proposed by the International Study Group on Pancreatic Surgery[13,14]. In-hospital mortality was taken under consideration when death occurred within the first 90 postoperative days. In the second postoperative week, imaging tests (computed tomography or Doppler ultrasound of the abdomen) were routinely requested. Additional tests aiming to assess MPA patency were conducted during the regular follow-up of patients with neoplasia or, when it was not the case, they were required at yearly intervals for the first three years.

RESULT

Seventy-five pancreatectomies were performed during the study period. Of these, it was necessary to perform MPA resection in 10 cases, which were considered as the study sample. In nine of these patients, the vascular procedure was performed during pancreaticoduodenectomy, whereas, in one of them, central pancreatectomy was the primary performed procedure. Half of the sample consisted of male patients. The average age was 55.7 years (40-76). As for the underlying disease, pancreatic adenocarcinoma was the most prevalent one among half of the samples (50%), and the second one was Frantz's tumor which was found in two cases (20%) (Table 1). Although, as a rule, pancreatic cystadenoma has no indication for surgery, if there is suspicion of mucinous lesion or if the lesion grows - as it was observed in a single patient who attended the current study -, thus the lesion's removal was indicated. The segmental resection was performed in the transverse colon of one of the patients with pancreatic adenocarcinoma, due to local invasion by the tumor.
Table 1

List of diseases, tumor size and technical features related to the MPA reconstruction (n=10)

nDiseasesTumor sizeType of venous resectionExtent of venous resectionType of reconstruction
1Pancreatic adenocarcinoma4 cmCircumferential resection including PV/ SMV with ligation of SV4,0 cmPrimary anastomosis of the vascular stumps
2Frantz’s tumor7,0 cmCircumferential resection including PV/ SMV with ligation of SV6,0 cmVenous graft (with SV)
3Papillary adenocarcinoma2,3 cmIsolated circumferential resection of  PV2,0 cmPrimary anastomosis of the vascular stumps
4Pancreatic adenocarcinoma3,0 cmTangential resection of SMV1,5 cmSMV plasty
5Pancreatic adenocarcinoma5,5 cmCircumferential resection including PV/ SMV with ligation of SV4,5 cmPrimary anastomosis of the vascular stumps
6Cholangiocarcinoma of the distal common bile duct7,5 cmCircumferential resection including PV/ SMV with ligation of SV5,0 cmGraft with PTFE prosthesis
7Pancreatic adenocarcinoma1,9 cmIsolated circumferential resection of  PV2,0 cmPrimary anastomosis of the vascular stumps
8Pancreatic adenocarcinoma3,0 cmTangential resection of MPA confluence3,0 cmGraft with PTFE prosthesis
9Serous cystadenoma7,0 cmIsolated circumferential resection of  SMV1,5 cmPrimary anastomosis of the vascular stumps
10Frantz’s tumor4,0 cmTangential resection of MPA confluence5,0 cmVenous graft (with IJV)

n=patient number; PV=portal vein; SMV=superior mesenteric vein; SV=splenic vein; MPA= mesenteric portal axis; PTFE= polytetrafluoroethylene; VJI= internal jugular vein

List of diseases, tumor size and technical features related to the MPA reconstruction (n=10) n=patient number; PV=portal vein; SMV=superior mesenteric vein; SV=splenic vein; MPA= mesenteric portal axis; PTFE= polytetrafluoroethylene; VJI= internal jugular vein Most of the patients in the sample (7 cases=70%) was subjected to isolated circumferential resection of the portal vein, superior mesenteric vein or of the confluence between them. Tangential resection was performed in the other three cases (30%). The type of vascular reconstruction was intraoperatively defined depending on the circumferential extent of the tumor's involvement. In most cases, such reconstruction was performed with primary suture of the vascular stumps (6 cases=60%) (Figure 1).
Figure 1

Ilustration of pancreaticoduodenectomy after releasing the surgical specimen and of the type of vascular reconstruction after resecting part of the MPA: A) pancreaticoduodenectomy surgical specimens were dissected and released, and attached only by tumor infiltration in the portal vein; B) vascular reconstruction by means of primary suture of the vascular stumps

Ilustration of pancreaticoduodenectomy after releasing the surgical specimen and of the type of vascular reconstruction after resecting part of the MPA: A) pancreaticoduodenectomy surgical specimens were dissected and released, and attached only by tumor infiltration in the portal vein; B) vascular reconstruction by means of primary suture of the vascular stumps In two cases (20%) it was necessary to perform venous grafting (Figure 2) and in two other cases (20%), the polytetrafluoroethylene prosthesis (Table 1 and Figure 3) was used.
Figure 2

Exemplification of vascular reconstruction by means of splenic vein graft PV=portal vein; SMV=superior mesenteric vein

Figure 3

Use of graft with polytetrafluoroethylene vascular prosthesis: A) interposition of the prosthesis between the superior mesenteric vein and the portal vein; B) use of it after isolated tangential resection of the portal vein

Exemplification of vascular reconstruction by means of splenic vein graft PV=portal vein; SMV=superior mesenteric vein Use of graft with polytetrafluoroethylene vascular prosthesis: A) interposition of the prosthesis between the superior mesenteric vein and the portal vein; B) use of it after isolated tangential resection of the portal vein The surgery time ranged from 480-600 min (average=556 min) and postoperative hospitalization time ranged from 9-114 days (average=34.8 days). Morbidity rate was of 60%. Clinical pancreatic fistula (grades B and C) was found in three cases (30%). Intraperitoneal bleeding and delayed gastric emptying occurred, respectively, in two (20%) and one (10%) of the cases. Biliary fistula and fecal peritonitis were identified in one patient each. The reoperation rate was of 40%, and it happened as a consequence of fecal peritonitis (in the case in which segmental colectomy was performed), intraperitoneal bleeding, biliary fistula, and pancreatic fistula. Mortality rate was of 10%. The only death case occurred on the 12th postoperative day and it due to intraperitoneal bleeding resulting from a splenic vein lesion that led the patient to re-operation. Although the surgeon managed to control the bleeding, the patient developed acute renal failure and coagulopathy. Anastomosis patency was evaluated in all patients during the postoperative period. On average, two imaging examinations were performed in each patient. Computed tomography of the abdomen with intravenous contrast was the examination performed in nine cases (90%). In 80% of these cases, there was MPA patency. In one patient (case 2), there was stenosis on 80% of the splenic vein graft and the development of collateral veins in the mesentery and stomach was identified four years after the procedure. Stenosis was corrected by means of metallic stent implantation. In another patient (case 8), right portal vein thrombosis was found as a consequence of liver metastasis. Patients' survival is shown in Table 2. Compatible with advanced stage (IIB) which was observed in 80% of patients with pancreatic adenocarcinoma, the average survival in this group was of 15 months (4-24). The two patients with Frantz's tumor and the patient with serous cystadenoma remained alive, without disease recurrence and with patent MPA.
Table 2

List of diseases, tumor stage (according to the TNM UICC classification 7th edition) and survival (n=10)

nDiseaseTumor stageSurvival
1Pancreatic adenocarcinomaT3N1M0 / IIB24 months
2Frantz’s tumor_Free of the disease for 5 years and 1 month
3Papillary adenocarcinomaT3N0M0 / IIAIntraoperative death
4Pancreatic adenocarcinomaT3N1M0 / IIB11 months
5Pancreatic adenocarcinomaT3N1M0 / IIB4 months
6Cholangiocarcinoma of the distal common bile ductT3N1M0 / IIB9 months
7Pancreatic adenocarcinomaT2N0M0 / IB23 months
8Pancreatic adenocarcinomaT3N1M0 / IIB13 months
9Serous cystadenoma_Free of the disease for 8 months
10Frantz’s tumor_Free of the disease for 2 months

n=patient number

List of diseases, tumor stage (according to the TNM UICC classification 7th edition) and survival (n=10) n=patient number

DISCUSSION

There is no doubt that vascular resection and reconstruction are feasible and they allow more radical surgeries in pancreatic tumors involving the vascular elements composing the MPA[5]. Such fact was observed in the current series. The two controversial aspects of this procedure concern its comparison with the pancreaticoduodenectomy, in which vascular resection is not necessary. Would morbimortality and survival be similar in both procedures? Yuet al.[15], in a recent meta-analysis, found 22 comparative studies on pancreatectomy with or without vascular resection, thus demonstrating that although the vascular resection group showed longer operative time and blood loss, there was no difference in overall morbidity or even in mortality. On the other hand, Castleberry et al.[3] used data from the American College of Surgeons' national registry, involving 3582 patients subjected to pancreaticoduodenectomy from 2005 to 2009, of which 281 patients underwent vascular resection. The authors found higher morbimortality related to the group that underwent resection. A possible explanation for such discrepancy may be related to the known superiority of results observed in uni-institutional surgical series when comparing them with those from surveys involving large numbers of services with varied experience. There was high morbidity in this series, and it was more related to the larger tumor sizes and surgery complexity than it was to the consequence of mesenteric ischemia or local technical complication from vascular reconstruction. This can be evidenced by the average operative time of 556 min, which was longer than that observed by the group in other published series of pancreaticoduodenectomies[1]. In fact, it was possible to correlate the vascular clamping as a causal factor for the development of pancreatic fistula and anastomotic bleeding in only one patient in the current study. This patient needed two venous reconstructions, since the primary suture of the vascular stumps showed tension and it led to immediate thrombosis at the anastomosis level. The problem was corrected by means of graft with polytetrafluoroethylene vascular prosthesis. As a consequence, clamping time was too long (100 min) and it turned the intestinal loops swollen and friable by venous stasis, thus contributing to the development of pancreatic fistula and gastrointestinal bleeding, both of grade C. The oncologic benefit was another concern. Currently, there is great debate related to long-term survival of vascular resection in pancreatic cancer surgery. In reviewing the literature on the subject, Ramacciato et al.[9] selected 12 studies that covered a total of 399 patients subjected to pancreaticoduodenectomy with associated MPA resection. The survival median ranged from 13-22 months, whereas the five-year survival rate ranged from 8.4 to 18%. As a further finding of the study, 10 living patients (48%) were found 10 years after the surgical procedure. The authors, based on their findings, recommended the MPA resection with vascular reconstruction, whenever feasible, in all patients who need it during pancreaticoduodenectomy. Two recent case series publications involving more than 100 patients suggest inferior outcomes in pancreaticoduodenectomy associated with vascular resection when compared with pancreaticoduodenectomy as a single procedure[7,12]. This viewpoint is contrary to that advocated by the MD Anderson Hospital group who, 18 years ago, suggested that the MPA tumor invasion is not associated with any histological parameters of tumor aggressiveness and poor prognosis, but it is only a reflex of the tumor emergence near the MPA[5]. The small number of patients with pancreatic adenocarcinoma in the current series prevents any valid conclusion about prognosis. However, according to this sample, one can suggest that most cases had advanced diseases with large tumors and lymph node impairment, which was consistent with the median survival of 15 months and a null survival rate at five years. It is noticed that the tumors that invade the MPA are, in general, advanced and such aspect should be discussed with the patient prior to their surgical indication. In this advanced disease scenario, neoadjuvant chemotherapy and radiotherapy are attractive possibilities that have been practiced in large centers[4]. From this experience and based on the current literature, some important technical details are considered as important: 1) completely release the specimen prior to vascular resection allowing smaller clamping time for vascular reconstruction with little splanchnic congestion and assessing the tumor involvement in the superior mesenteric artery before resection - some of the various types of technical possibilities that address the superior mesenteric artery ("artery first approach") should be practiced[10]; 2) the approximation of the vascular stumps is the best reconstruction technique since it is quick and allows suturing the veins with the same caliber; 3) the surgical team should be prepared for the different MPA reconstruction possibilities, since the length of the resected vein alone does not necessarily define whether stumps approximation will occur without tension. The splenic vein preservation may limit the approximation in isolated resections of the portal vein or inferior mesenteric vein[11]. It happened in one case, and required the use of a graft in order to correct intraoperative thrombosis.

CONCLUSION

The mesenteric-portal axis resection is a valid technical practice. It should be taken under consideration after contemplating not only the patients' clinical condition, the technical and the anatomical status of tumor infiltration in the mesenteric-portal axis, but also - and not least important -, considering the expected survival based on the patient's cancer prognosis.
  15 in total

Review 1.  Postoperative pancreatic fistula: an international study group (ISGPF) definition.

Authors:  Claudio Bassi; Christos Dervenis; Giovanni Butturini; Abe Fingerhut; Charles Yeo; Jakob Izbicki; John Neoptolemos; Michael Sarr; William Traverso; Marcus Buchler
Journal:  Surgery       Date:  2005-07       Impact factor: 3.982

2.  Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS).

Authors:  Moritz N Wente; Claudio Bassi; Christos Dervenis; Abe Fingerhut; Dirk J Gouma; Jakob R Izbicki; John P Neoptolemos; Robert T Padbury; Michael G Sarr; L William Traverso; Charles J Yeo; Markus W Büchler
Journal:  Surgery       Date:  2007-11       Impact factor: 3.982

Review 3.  'Artery-first' approaches to pancreatoduodenectomy.

Authors:  P Sanjay; K Takaori; S Govil; S V Shrikhande; J A Windsor
Journal:  Br J Surg       Date:  2012-05-09       Impact factor: 6.939

4.  Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation.

Authors:  Jeannelyn S Estrella; Asif Rashid; Jason B Fleming; Matthew H Katz; Jeffrey E Lee; Robert A Wolf; Gauri R Varadhachary; Peter W T Pisters; Eddie K Abdalla; Jean-Nicolas Vauthey; Hua Wang; Henry F Gomez; Douglas B Evans; James L Abbruzzese; Huamin Wang
Journal:  Cancer       Date:  2011-07-06       Impact factor: 6.860

5.  The impact of vascular resection on early postoperative outcomes after pancreaticoduodenectomy: an analysis of the American College of Surgeons National Surgical Quality Improvement Program database.

Authors:  Anthony W Castleberry; Rebekah R White; Sebastian G De La Fuente; Bryan M Clary; Dan G Blazer; Richard L McCann; Theodore N Pappas; Douglas S Tyler; John E Scarborough
Journal:  Ann Surg Oncol       Date:  2012-08-30       Impact factor: 5.344

6.  Pancreaticoduodenectomy with vascular resection: margin status and survival duration.

Authors:  Jennifer F Tseng; Chandrajit P Raut; Jeffrey E Lee; Peter W T Pisters; Jean-Nicolas Vauthey; Eddie K Abdalla; Henry F Gomez; Charlotte C Sun; Christopher H Crane; Robert A Wolff; Douglas B Evans
Journal:  J Gastrointest Surg       Date:  2004-12       Impact factor: 3.452

7.  Adverse tumor biology associated with mesenterico-portal vein resection influences survival in patients with pancreatic ductal adenocarcinoma.

Authors:  F Wang; A J Gill; M Neale; V Puttaswamy; S Gananadha; N Pavlakis; S Clarke; T J Hugh; J S Samra
Journal:  Ann Surg Oncol       Date:  2014-02-21       Impact factor: 5.344

8.  Rationale for en bloc vein resection in the treatment of pancreatic adenocarcinoma adherent to the superior mesenteric-portal vein confluence. Pancreatic Tumor Study Group.

Authors:  G M Fuhrman; S D Leach; C A Staley; J C Cusack; C Charnsangavej; K R Cleary; A K El-Naggar; C J Fenoglio; J E Lee; D B Evans
Journal:  Ann Surg       Date:  1996-02       Impact factor: 12.969

Review 9.  Postpancreatectomy hemorrhage (PPH): an International Study Group of Pancreatic Surgery (ISGPS) definition.

Authors:  Moritz N Wente; Johannes A Veit; Claudio Bassi; Christos Dervenis; Abe Fingerhut; Dirk J Gouma; Jakob R Izbicki; John P Neoptolemos; Robert T Padbury; Michael G Sarr; Charles J Yeo; Markus W Büchler
Journal:  Surgery       Date:  2007-07       Impact factor: 3.982

Review 10.  Does portal-superior mesenteric vein invasion still indicate irresectability for pancreatic carcinoma?

Authors:  Giovanni Ramacciato; Paolo Mercantini; Niccolò Petrucciani; Valentina Giaccaglia; Giuseppe Nigri; Matteo Ravaioli; Matteo Cescon; Alessandro Cucchetti; Massimo Del Gaudio
Journal:  Ann Surg Oncol       Date:  2009-01-21       Impact factor: 5.344

View more
  3 in total

1.  SOLID PSEUDOPAPILLARY NEOPLASM OF THE PANCREAS.

Authors:  Jorge Roberto Marcante Carlotto; Franz Robert Apodaca Torrez; Adriano Miziara Gonzalez; Marcelo Moura Linhares; Tarcisio Triviño; Benedito Herani-Filho; Alberto Goldenberg; Gaspar de Jesus Lopes-Filho; Edson José Lobo
Journal:  Arq Bras Cir Dig       Date:  2016 Apr-Jun

2.  UNDERSTANDING THE INTERNATIONAL CONSENSUS FOR ACUTE PANCREATITIS: CLASSIFICATION OF ATLANTA 2012.

Authors:  Gleim Dias de Souza; Luciana Rodrigues Queiroz Souza; Ronaldo Máfia Cuenca; Bárbara Stephane de Medeiros Jerônimo; Guilherme Medeiros de Souza; Vinícius Martins Vilela
Journal:  Arq Bras Cir Dig       Date:  2016 Jul-Sep

3.  Pancreatoduodenectomy combined with portal-superior mesenteric vein resection and reconstruction with interposition grafts for cancer: a meta-analysis.

Authors:  Wei Song; Qifan Yang; Linghui Chen; Qiang Sun; Dongkai Zhou; Song Ye; Zhenhua Hu; Liming Wu; Liming Feng; Shusen Zheng; Weilin Wang
Journal:  Oncotarget       Date:  2017-09-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.